Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Novartis Pharmaceuticals
Scientific Title
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation